Results of recent large cholesterol-lowering trials and implications for clinical management

American Journal of Cardiology

Volumn 79, Issue 12, 1997, Pages 1663-1666

  Gotto Jr , Antonio M ^a  

^a And Provost for Medical Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

EID: 0343036294     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00218-X     Document Type: Article

References (20)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333:1995;1301-1307.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
3. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 345:1995;1274-1275.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E. for the Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 335:1996;1001-1009.
5. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 76:1995;69C-77C.
6. Wong ND, Wilson PWF, Kannel WB. Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med. 115:1991;687-693.
7. Gotto AM, Gorry GA, Thompson JR, Cole JS, Trost R, Yeshurun D, DeBakey ME. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. Circulation. 56:1977;875-883.
8. Rose G, Hamilton PJS, Keen H, Reid DD, McCartney P, Jarrett RJ. Myocardial ischaemia, risk factors and death from coronary heart-disease. Lancet. 1:1977;105-109.
9. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
10. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 336:1997;153-1162.
11. Thompson GR, Hollyer J, Waters DD. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr Opin Lipidol. 6:1995;386-388.
12. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 44:1993;121-131.
13. Brown BG, Zhao X-Q, Sacco DE, Alberts JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
14. Gotto AM Jr. Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. Cleve Clin J Med. 63:1996;31-41.
15. Salonen R, Nyyssonen K, Porkkala-Sarataho E, Salonen JT. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol. 76:1995;34C-39C.
16. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 332:1995;488-493.
17. Treasure CB, Klein L, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 332:1995;481-487.
18. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
19. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 87:1996;6-12.
20. Cattel L, Cerruti M, Balliano G, Viola F, Grosa G, Rocco F, Brusa P. 2,3-Oxidosqualene cyclase: from azasqualenes to new site-directed inhibitors. Lipids. 30:1995;235-246.